A PEER-REVIEWED JOURNAL OF RESEARCH AND CLINICAL MEDICINEISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Successful Use of Adalimumab in Children with Uveitis-Associated Juvenile Idiopathic Arthritis

DOI:10.31550/1727-2378-2021-20-10-73-75
For citation: Aksenov A.V., Ivanovskaya E.A. Successful Use of Adalimumab in Children with Uveitis-Associated Juvenile Idiopathic Arthritis. Doctor.Ru. 2021; 20(10): 73–75. (in Russian). DOI: 10.31550/1727-2378-2021-20-10-73-75
30 november 2021

Objective of the Paper: To describe clinical cases of successful use of adalimumab in children with uveitis-associated juvenile idiopathic arthritis (JIA).

Key Points. One of the extraarticular manifestations of JIA is uveitis, i. e. inflammation of the vascular tract of the eye. JIA-associated uveitis is diagnosed primarily in small girls with oligoarthritis, early seronegative polyarthritis; in patients with arthritis associated with enthesitis and psoriatic arthritis. The article describes clinical cases of the use of adalimumab in JIA and uveitis where the therapy with methotrexate and topical glucocorticosteroids fails.

Conclusion. Uveitis-associated JIA is one of the most disabling forms of JIA, since, despite timely and adequate management, very often it results in severe ocular complications: cataract, glaucoma and even blindness. Adalimumab, a human anti-TNFα monoclonal antibody, is available and it helps in achieving uveitis remission where methotrexate and topical glucocorticosteroids fail, as well as in delaying ocular complications.

Contributions: Aksenov, A.V. — thematic publications reviewing, text of the article, approval of the manuscript for publication; Ivanovskaya, E.A. — examination, material collection and therapeutic interventions.

Conflict of interest: The authors declare that they do not have any conflict of interests

A.V. Aksenov (Corresponding author) — South Ural State Medical University of the Ministry of Health of the Russian Federation; 64 Vorovskiy Str., Chelyabinsk, Russian Federation 454092. eLIBRARY.RU SPIN: 8688-8874. E-mail: alexandr.axyonov@yandex.ru

E.A. Ivanovskaya — Children’s City Clinical Hospital No.8; 2 Druzhby Str., Chelyabinsk, Russian Federation 454047. E-mail: Ivanovskaya.Elena@yandex.ru

Доктор.ру

Received: 21.05.2021

Accepted: 09.08.2021

30 November 00:00
REFERENCES
  1. Alekseeva E.I., Litvitskiy P.F.; Baranov A.A., ed. Juvenile rheumatoid arthritis: aetiology, pathogenesis, clinical findings, algorithms of diagnosis and management. Manual for medical professional, teachers, and scientists. M.: Vedi; 2007. 368 p. (in Russian)
  2. Seraya V.A., Zholobova E.S., Vitebskaya A.V. et al. Dynamics of growth of children with systemic form of juvenile idiopathic arthritis during therapy with tocilizumab and other biological agents. Clinical Practice in Pediatrics. 2016; 11(2): 15–22. (in Russian). DOI: 10.20953/1817-7646-2016-2-15-22
  3. Horneff G., Schulz A.C., Klotsche J. et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile rheumatoid arthritis patients from the BIKER registry. Arthritis Res. Ther. 2017; 19(1): 256. DOI: 10.1186/s13075-017-1462-2
  4. Kikuchi J., Kondo T., Shibata A. et al. Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. Mod. Rheumatol. 2018; 28(3): 444–51. DOI: 10.1080/14397595.2017.1366092
  5. Pardeo M., De Benedetti F., Wang J. et al. Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. J. Rheumatol. 2019; 46(6): 1117–26. DOI: 10.3899/jtheum.180795
  6. Aksenov A.V., Ivanovskaya Е.А. Successful use of tocilizumab in a child with systemic juvenile idiopathic arthritis. Doctor.Ru. 2021; 20(3): 70–2 (in Russian). DOI: 10.31550/1727-2378-2021-20-3-70-72
  7. Chomakhidze A.M., Alekseeva E.I., Denisova R.V. The experience of successful use of adalimumab in a patient with juvenile arthritis associated with enthesitis and uveitis. Pediatric Pharmacology. 2017; 14(4): 294–9. (in Russian). DOI: 10.15690/pf.v14i4.1761
  8. Sevost’yanov V.K., Zholobova E.S. Uveitis associated with juvenile idiopathic arthritis according to the register of children receiving engineered biological therapy in Moscow. Russian Medical Journal. 2017; 12: 924–8. (in Russian)
  9. Burgos-Vargas R., Tse S.M.L., Horneff G. et al. Efficacy and safety of adalimumab in pediatric patient with enthesitis related arthritis. Arthritis Rheumatol. 2014; 66(S3): S4. DOI: 10.1002/art.38414

Похожие статьи

News

1 October 10:52
A New Issue of Doctor.Ru Internal Medicine, Vol. 21, No. 6 (2022), Published

Find original articles and reviews covering various aspects of сardiology, gastroenterology, internal medicine and the interview with Professor Alexey Nikolaevich Kalyagin

7 July 17:16
A New Issue of Doctor.Ru Neurology Psychiatry, Vol. 21, No. 4 (2022), Published

Find original articles and reviews covering various aspects of neurology, psychiatry and the interview with Professor Alexander Vitalievich Amelin

12 May 11:25
A New Issue of Doctor.Ru Pediatrics, Vol. 21 No. 3 (2022), Published

See the original papers, reviews and clinical cases in headings Pulmonology, Rheumatology, Endocrinology, Neurology, Cross-disciplinary approach and Interview with with an Honoured Scientist of the Sakha (Yakutia) Republic Professor Maria Vasilievna Khandy

4 May 10:02
A New Issue of Doctor.Ru Internal Medicine, Vol. 21, No. 2 (2022), Published

Find original articles and reviews covering various aspects of gastroenterology, internal medicine, rheumatology, endocrinology, special section of postgraduate training and the interview with Professor Dmitry Alexeevich Sychev

18 March 00:00
A New Issue of Doctor.Ru Gynecology, Vol. 21 No. 1 (2022), Published

Find original articles and reviews covering various aspects of obstetrics, perinatology and gynecology, and the interview with Feldberg Dov, MD

All news